When Nicole Smith took her son’s EpiPen prescription to her local Walgreens she balked at the $600 price quote for a two-pack. Her high-deductible health plan meant Mylan’s “$0 co-pay card” would only bring the cost down to $500.
The story is an all-too-familiar one: company buys dated drug, raises prices and impedes patient access to life-saving treatment in the process.
This time, the target of the tired narrative is a medical device with an unusual amount of brand name recognition, effectively no alternatives and a growing patient population
The price of the EpiPen, which treats emergency allergic reactions, has climbed sixfold over the last several years. While inflation is below zero.
There is a solution to this price gouging, but would the Presidential Candidates say something about it? Vote your Conscious. Just a thought.
No comments:
Post a Comment